Pharmaceutical Support
 
  
 
        
      
Genotoxic Impurities Reference List
      
      Concept  Papers for ICH Guidances  Relevant to  Genotoxic Impurities
    
 M7: Assessment and Control of  DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential  Carcinogenic Risk; Dated 27 November 2009; Endorsed by the ICH Steering  Committee on 9 June 2010.  See Link:  M7:  Assessment and Control of DNA Reactive (Mutagenic) Impurities Concept Paper
 M7: Assessment and Control of  DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential  Carcinogenic Risk; Dated 27 November 2009; Endorsed by the ICH Steering  Committee on 9 June 2010.  See Link:  M7:  Assessment and Control of DNA Reactive (Mutagenic) Impurities Concept Paper
 Final Concept Paper Q3D:  Impurities: Guideline for Metal Impurities; Dated 17 July 2009; Endorsed by the  Steering Committee on 29 October 2009.   See Link: Q3D  Concept Paper: Metal Impurities
 Final Concept Paper Q3D:  Impurities: Guideline for Metal Impurities; Dated 17 July 2009; Endorsed by the  Steering Committee on 29 October 2009.   See Link: Q3D  Concept Paper: Metal Impurities
      
    
Genotoxic Impurities Regulatory Guidances
 European Medicines Agency  Committee for Medicinal Products for Human Use: Guideline on the Limits of  Genotoxic Impurities; Dated 28 June 2006; Finalized  01 January 2007.  See Link:  EMA  Genotoxic Impurities Guideline
 European Medicines Agency  Committee for Medicinal Products for Human Use: Guideline on the Limits of  Genotoxic Impurities; Dated 28 June 2006; Finalized  01 January 2007.  See Link:  EMA  Genotoxic Impurities Guideline
 US Department of Health and  Human Services, food and Drug Administration; Genotoxic and Carcinogenic  Impurities in Drug Substances and Products:   Recommended Approaches; Dated December 2008.  FDA Draft  Genotoxic Impurities Guidance
 US Department of Health and  Human Services, food and Drug Administration; Genotoxic and Carcinogenic  Impurities in Drug Substances and Products:   Recommended Approaches; Dated December 2008.  FDA Draft  Genotoxic Impurities Guidance
  
PhRMA Position Paper
 Müller L, Mauthe RJ, Riley CM,  Andino MM, Antonis DD, Beels C, DeGeorge J, De   Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S,  Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK,  O'Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determining,  testing, and controlling specific impurities in pharmaceuticals that possess  potential for genotoxicity. Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211.  Epub 2006 Jan 18. PubMed PMID: 16412543. Link to Pubmed Abstract for  Muller et. al.
 Müller L, Mauthe RJ, Riley CM,  Andino MM, Antonis DD, Beels C, DeGeorge J, De   Knaep AG, Ellison D, Fagerland JA, Frank R, Fritschel B, Galloway S,  Harpur E, Humfrey CD, Jacks AS, Jagota N, Mackinnon J, Mohan G, Ness DK,  O'Donovan MR, Smith MD, Vudathala G, Yotti L. A rationale for determining,  testing, and controlling specific impurities in pharmaceuticals that possess  potential for genotoxicity. Regul Toxicol Pharmacol. 2006 Apr;44(3):198-211.  Epub 2006 Jan 18. PubMed PMID: 16412543. Link to Pubmed Abstract for  Muller et. al.